sought no further treatment while 2 underwent autologous PVS placement. The majority of patients who failed MPQ injection reported subjective improvement and reduced pad usage. Higher parity was associated with MPQ failure (p[0.027).
INTRODUCTION AND OBJECTIVES: Macroplastique (MPQ)
is a urethral bulking agent used in the treatment of stress urinary incontinence (SUI) in women with intrinsic sphincter deficiency (ISD). Ghoniem et al showed durability of MPQ success up to 2 years. The purpose of this study is to evaluate the safety and efficacy of MPQ in women with SUI due to ISD who completed a 3 year follow-up in this post market study.
METHODS: This is a retrospective review of prospectively collected data of 276 subjects enrolled in a multicenter study between October 2008-August 2017. 70 subjects completed 3 years of follow up. Subjects were treated with up to two MPQ injections and followed at 3,12, 24, and 36 months. Stamey grade (0[ continent, 1[ incontinence with vigorous activity, 2[ incontinence with minimal activity and 3[ total incontinence) and I-QoL questionnaire divided into 3 subscales were assessed at baseline, 12, 24,and 36 months post injection. Patient Global Impression of Satisfaction (PGI-S) was assessed at 36 months. Success is defined as improvement to Stamey grade 0 or 1 at 36 months. Safety assessment is reported on serious and non-serious adverse events (AE). Two-sided binomial test was used to test the overall success rate, while linear mixed effect model with patient-level random effect was used to examine longitudinal trends over the 3-year study period.
RESULTS: The majority of patients were white with mean age 63.3 years. At 36 months 21/70 (30%) of patients reported Stamey grade 0 and 28/70 (40%) had Stamey grade 1. Overall satisfaction was 68% at 36 months. 27/70 (38.5%) patients report they were very satisfied on PGI-S at 36 months. I-QoL scores and the subscales were significantly improved at 12, 24 and 36 months from baseline (p <0.0001) and remained stable. The composite success rate (QoL, PGI-S and Stamey grade improvement) was 51.4%. Transient dysuria 3.2%, hematuria 6%, pain at the injection site 1.6% and urinary tract infection 2% were the most common AE that occurred within the first 3 months post injection. No serious AE were reported. CONCLUSIONS: At 3 years, MPQ is safe and efficacious for the treatment of SUI secondary to ISD in women. The overall satisfaction is sustained from baseline to 3 years post injection.
Source of Funding: Unrestricted grant from Cogentix

PD02-12 REDUCED EXPRESSION OF UROPLAKIN-3A FOLLOWING CYSTOSCOPY WITH FULGURATION OF TRIGONITIS IN WOMEN WITH RECURRENT UTI
INTRODUCTION AND OBJECTIVES: Recurrent urinary tract infection (RUTI) in has become an important clinical problem with limited therapeutic options. Cystoscopy with fulguration of trigonitis (CFT) is a treatment option for women for whom antibiotic therapy is no longer effective or well-tolerated. CFT effectively resolves trigonitis and prevents RUTI in approximately 70% of cases, but the scientific basis for this is poorly understood (1). One hypothesis is that the fulgurated areas no longer express the surface proteins, such as uroplakin-3, that pathogens use to attach to and invade the urothelium (2). In this study, we evaluated the expression of uroplakin-3a along the luminal surface of umbrella cells in biopsies from both naive and previously fulgurated bladder regions.
METHODS: Following IRB approval, cold cup bladder biopsies of both regions of visible cystitis (infected) and no visible cystitis (control) were obtained from postmenopausal women with antibiotic refractory, uncomplicated RUTI undergoing CFT under anesthesia. In patients with prior CF, the "control" region was the previously fulgurated region as cystitis was never visible in these areas. Control and infected
